SpinChip Diagnostics has been acquired by French biotech company bioMérieux for 1.6 billion Norwegian kroner, enhancing bioMérieux's presence in the diagnostic sector.
Target Information
SpinChip Diagnostics, a portfolio company, has been sold to the French biotech firm bioMérieux. The transaction valued SpinChip Diagnostics at 1.6 billion Norwegian kroner and was announced in January 2025. This significant valuation was largely realized towards the end of the previous year, positively impacting Investinor's financial results for 2024.
As a pioneer in its sector, SpinChip Diagnostics specializes in advanced medical testing solutions, contributing to the growing trend of innovation in the healthcare diagnosis space. This sale represents not just a financial transaction but also a strategic alignment with bioMérieux's commitment to enhance diagnostic capabilities worldwide.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Norway
NORWAY's biotech and diagnostic sectors are experiencing accelerated growth, predominantly fueled by increased investment in research and development. Norway is home to numerous innovative healthcare startups, driven by
Similar Deals
bioMérieux
invested in
SpinChip Diagnostics
in 2025
in a Other deal
Disclosed details
Transaction Size: $139M
Enterprise Value: $139M